

Special Issue

Next Generation Sequencing for Cancer Diagnostics

Message from the Guest Editor

Cancer is a leading cause of death worldwide, and accounted for ~10 million cancer deaths in 2020. The introduction of next-generation sequencing (NGS) technologies in clinical oncology laboratories has allowed the detection of somatic alterations, including single nucleotide variants, small indels, copy number variants and structural variants, on a genome-wide scale. Large-scale sequencing studies have illustrated the genomic landscapes of different cancers, thus leading to the identification of novel driver mutations, prognostic markers and a large number of therapeutic targets. Recent progress in genomic analysis using NGS technology has enabled the comprehensive detection of mutations, as well as the tumor mutation burden (TMB), in patient tumors, a biomarker for immunotherapy. NGS-based techniques have also been applied at the transcriptomic and epigenomic levels in order to accelerate our understanding of cancer biology and clinical trials for novel therapeutics. In this issue of *Cancers*, we would like to present a review of the currently available data on the utility of NGS-based applications for cancer diagnostics.

Guest Editor

Dr. Gayatri Mohapatra

Laboratory of Genomic Medicine, Department of Pathology, University of Illinois Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

closed (15 November 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/168358

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)